TABLE 1] Descriptive Characteristics and Demographics of the Study Group
Descriptive Characteristic
Control Group
(n ¼ 231)
Normal Spirometry Group
(n ¼ 2,090)
Asthma Group
(n ¼ 265)
COPD Group
(n ¼ 330)
PRISm Group
(n ¼ 172)
Age, y 61.5 (14.6) 59.2 (15.3) 58.7 (16.0) 66.1 (11.3) 60.9 (14.4)
Female, No. (%) 98 (42) 1082 (52) 116 (44) 121 (37) 86 (50)
Income, No. (%)
< CAD $30,000 10 (4.5) 209 (10) 18 (7) 51 (15) 34 (20)
$ CAD $30,000 211 (91) 1522 (73) 204 (77) 213 (65) 106 (62)
Income not reported 10 (4.5) 359 (17) 43 (16) 66 (20) 32 (18)
BMI, kg/m2 28.35 (5.39) 30.50 (6.60) 30.65 (7.03) 28.57 (5.86) 34.66 (8.80)
BMI, No. (%)
Not overweight 68 (29) 422 (20) 60 (23) 98 (30) 20 (12)
Overweight 86 (37) 675 (32) 72 (27) 127 (38) 37 (21)
Obese 71 (31) 812 (39) 104 (39) 91 (28) 77 (45)
Morbidly obese 6 (3) 181 (9) 29 (11) 14 (4) 38 (22)
Prebronchodilator
spirometry
FEV1, L 2.98 (0.76) 2.89 (0.81) 2.53 (0.78) 2.01 (0.71) 2.06 (0.56)
FEV1, % predicted 102.5 (15.0) 99.6 (14.0) 83.7 (13.6) 70.3 (17.0) 70.7 (7.7)
FEV1/FVC 0.74 (0.07) 0.76 (0.06) 0.69 (0.07) 0.58 (0.08) 0.77 (0.06)
Post-bronchodilator
spirometry
FEV1, L 3.01 (0.8) 2.98 (0.84) 2.89 (0.86) 2.16 (0.71) 2.09 (0.57)
FEV1 % predicted 105.9 (14.6) 102.6 (14.0) 95.6 (14.4) 75.5 (16.0) 71.6 (7.3)
FEV1/FVC 0.77 (0.07) 0.79 (0.06) 0.74 (0.06) 0.60 (0.09) 0.78 (0.06)
Change in FEV1
postbronchodilator, %
3.4 (4.7) 3.0 (3.7) 11.9 (3.9) 5.0 (5.4) 0.9 (3.9)
Comorbidities, No. (%)
Congestive heart failure 1 (0.4) 22 (1) 5 (2) 10 (3) 9 (5)
Coronary artery disease 24 (10) 180 (9) 24 (9) 64 (19) 31 (18)
Depression/anxiety 70 (30) 836 (40) 106 (40) 99 (30) 54 (31)
Diabetes mellitus 23 (10) 261 (12) 33 (12) 42 (13) 45 (26)
Hypertension 66 (29) 704 (34) 94 (35) 122 (37) 86 (50)
Anemia 31 (13) 351 (17) 44 (17) 42 (13) 23 (13)
Cancer 23 (10) 222 (11) 25 (9) 51 (15) 13 (8)
GERD 55 (24) 735 (35) 89 (34) 98 (30) 63 (37)
Liver disease 6 (3) 89 (4) 12 (5) 14 (4) 9 (5)
Renal disease 10 (4) 85 (4) 9 (3) 20 (6) 10 (6)
Stroke 5 (2) 72 (3) 5 (2) 15 (5) 11 (6)
Smoking status, No. (%)
Does not smoke 149 (65) 912 (44) 104 (39) 44 (13) 72 (42)
Previous tobacco use 77 (33) 839 (40) 118 (45) 158 (48) 68 (40)
Active tobacco use 4 (2) 324 (16) 41 (16) 128 (39) 29 (17)
Total pack-y 5.6 (11.8) 10.7 (16.5) 12.7 (17.9) 32.7 (27.2) 13.3 (19.6)
Total months of
occupational
exposurea
36.5 (112.5) 74.7 (193.1) 101.1 (278.9) 119.5 (262.4) 99.3 (263.2)
Data are presented as mean (SD) unless otherwise stated. GERD¼ gastroesophageal reﬂux disease; PRISm¼ preserved ratio impaired spirometry.
aOccupational exposure includes hard-rock mining, coal mining, sandblasting, working with asbestos, chemical/plastics manufacturing,ﬂour/feed/grain
milling, cotton/jute processing, foundry/steel milling, welding,ﬁre ﬁghting, farming, forestry, saw-milling, and working with paint/chemicals/fumes.
1300 Original Research [ 166#6 CHEST DECEMBER 2024 ]